COSTEM 2019 | Can third party CMV-specific T-cells replace drug therapy?

Name: Can third party CMV-specific T-cells replace drug therapy?
Uploaded: 2019-10-26T00:00:00.000Z
Duration: 48 s
Description: Per Ljungman, MD, PhD, Karolinska University Hospital, Solna, Sweden, evaluates third-party CMV-specific T-cells replacing drug therapy. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Per Ljungman • 26 Oct 2019

COSTEM 2019

General CAR-T

Per Ljungman, MD, PhD, Karolinska University Hospital, Solna, Sweden, evaluates third-party CMV-specific T-cells replacing drug therapy. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.